WPC
LGND icon

Waters Parkerson & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Waters Parkerson & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Buy
+730
New +$172K 0.01% 185
2024
Q4 		– Sell
-3,040
Closed -$304K – 186
2024
Q3 		$304K Buy
+3,040
New +$306K 0.02% 159

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Waters Parkerson & Co's LGND Position: Q2 2026 in Review

Waters Parkerson & Co opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 730 shares worth $231K. The stake represents 0.01% of the portfolio and ranks #185 among its holdings. This is a return to the name: Waters Parkerson & Co previously reported a position in LGND as recently as Q3 2024.

Waters Parkerson & Co first reported a position in LGND in Q3 2024 and has held it in 2 quarters since. The position peaked at $304K in Q3 2024. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Waters Parkerson & Co held 730 shares of Ligand Pharmaceuticals worth $231K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Waters Parkerson & Co position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.01% of Waters Parkerson & Co's portfolio in Q2 2026, its #185 holding.
  • Waters Parkerson & Co first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
  • Waters Parkerson & Co's Ligand Pharmaceuticals position peaked at $304K in Q3 2024.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Waters Parkerson & Co's 13F filing for Q2 2026, filed 30 Jul 2026.